Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Second or later bone marrow relapse (defined as M3 marrow or M2 marrow or M1 marrow but with MRD level ≥ 10E-3), or
Any marrow relapse after alloHSCT (defined as M3 marrow or M2 marrow or M1 marrow but with and MRD level ≥ 10E-3), or
Refractory to other treatments:
* For patients in first relapse: failure to achieve a CR following a full standard reinduction chemotherapy regimen
* For patients who have not achieved a first remission: failure to achieve remission following a full standard induction regimen
Subjects previously treated with blinatumomab may be eligible, if subject ended treatment for reason(s) other than disease progression or intolerability to blinatumomab (Note: This does not include patients who have already received blinatumomab treatment on this study, but refers only to patients outside of the 20130320 study)
